
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UCP4 CRISPR Activation Plasmid (h) | sc-417530-ACT | 20 µg | $397.00 |
Human SLC25A27 encodes uncoupling protein 4 (UCP4), a mitochondrial inner membrane carrier that modulates proton conductance to fine-tune oxidative phosphorylation efficiency and mitochondrial membrane potential. UCP4 activity influences cellular energy balance, reactive oxygen species handling, and stress-adaptive metabolism, particularly in tissues with high bioenergetic demand. Through its impact on mitochondrial coupling and redox homeostasis, UCP4 is studied in pathways linked to neuronal resilience, bioenergetic failure, and inflammation-associated metabolic reprogramming. Altered UCP4 expression has been associated with mitochondrial dysfunction phenotypes relevant to neurodegeneration and other disorders characterized by impaired mitochondrial energetics.
UCP4 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous SLC25A27 expression without altering the underlying DNA sequence.
UCP4 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the SLC25A27 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the SLC25A27 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous UCP4 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native SLC25A27 locus and enabling the study of UCP4-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of UCP4 pathway restoration in tumor cells with silenced or reduced SLC25A27 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.